Ƶ

MIND Diet and Cognitive Decline; Gene Therapy for Parkinson's; Curbing MS Fatigue

— News and commentary from the world of neurology and neuroscience

Ƶ MedicalToday
Neuro Break over a computer rendering of neurons.

The MIND diet was associated with in both Black and white older adults, but relationships appeared to vary with other lifestyle and vascular factors. (Alzheimer's and Dementia)

A meta-analysis identified in attention deficit-hyperactivity disorder and Parkinson's disease. (Nature Genetics)

A high dose of the AAV-GAD, which delivers the glutamic acid decarboxylase (GAD) gene to the subthalamic nucleus to boost levels of GABA, was safe, well tolerated, and showed improvement in motor scores in a small Parkinson's trial, MeiraGTx said.

CVN424, a , also was safe, well tolerated, and showed a clinically meaningful reduction in daily "off" time at 150 mg/day in Parkinson's disease, a phase II study showed. (eClinicalMedicine)

A tool to predict which patients are at risk of was published in JAMA Neurology.

A group of experts led by the American Headache Society, together with the National Institute of Neurological Disorders and Stroke and the International Headache Society, identified for the headache field.

Modafinil (Provigil), cognitive behavioral therapy, and a combination of the two were associated with similar reductions in the effects of at 12 weeks, the COMBO-MS trial showed. (Lancet Neurology)

Compared with conventional therapies, the risk of diseases rose after anti-tumor necrosis factor therapy across all indications, a meta-analysis found. (JAMA Neurology)

Mailed educational interventions directed at patients, caregivers, and clinicians didn't reduce of certain high-risk medications for people with Alzheimer's and dementia. (JAMA Internal Medicine)

  • Judy George covers neurology and neuroscience news for Ƶ, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more.